(Information sent by the signatory company)
MUMBAI, India, Feb. 1, 2024 /PRNewswire/ — Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical company, today announced its standalone and consolidated results for the third quarter (Q3). ) and the nine months (9 million) ended December 31, 2023.
Key Highlights for the Third Quarter and Nine Months of Fiscal 2024
Nandini Piramal, Chairman, Piramal Pharma Limited, explained, “We continue to build on our improved performance in FY24 with 14% YoY revenue growth in Q3 along with significant improvement in EBITDA margin. Our CDMO business is generating healthy growth with strong order inflows, especially for differentiated offerings and innovation-related work. Our inhalation anesthesia portfolio is recording good volume growth in our key US market and is also seeing increasing traction in the markets in the rest of the world. Our consumer healthcare business in India is generating steady growth driven by our powerful brands and our contribution. from the launch of new products.
On the sustainability front, we have set significant targets for reducing our Scope 1, 2 and 3 GHG emissions by fiscal year 2030. We are also working on multiple initiatives in the areas of water conservation, responsible waste disposal , gender diversity, employee safety, sustainable supply chain and community development.
We look forward to continuing our momentum in the fourth quarter and ending the financial year on a positive note.”
Key Business Highlights for Q3 FY24 and Nine Months of FY2020
Contract Development and Manufacturing Organization (CDMO):
Complex Hospital Generics (CHG):
Indian Consumer Healthcare (ICH):
* New promotion and commercial orders. These go beyond existing multi-year manufacturing relationships.
Third Quarter and Nine Months Fiscal 2024 Results Conference Call
Piramal Pharma Limited will host an investor/analyst conference call on January 31, 2024 from 5:00 p.m. m. to 5:45 p.m. m. (IST) to analyze its results for the third quarter and the nine months of fiscal year 2024.
Dial-in details for the call are as follows:
About Piramal Pharma Ltd:
Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, which sells over-the-counter products. Additionally, one of PPL’s associate companies, AbbVie Therapeutics India Private Limited (formerly Allergan India Pvt Ltd), a joint venture between Allergan (now part of AbbVie) and PPL, has emerged as one of the market leaders in the area. of ophthalmological therapy. Additionally, PPL has a minority investment in Yapan Bio Private Limited. In October 2020, PPL received a 20% strategic growth investment from the Carlyle Group.
For more information, visit: www.piramaI.com/pharmaI Twitter.
Logo – https://mma.prnewswire.com/media/1855206…
View original content: https://www.prnewswire.com/es/comunicados-de-prensa/piramal-pharma-limited-anuncia-resultados-consolidados-para-el-tercer-trimestre-y-nueve-meses-de-2024-302049712.html
